Using an Antagonist of Chimeric Receptor Antigen T Cell Therapy to Prevent Cytokine Storm in COVID-19: A Hypothesis
نویسندگان
چکیده
SARS-COV-2 pandemic is almost 3-years-old and remains a case for concern. An overwhelming production of pro-inflammatory cytokines in the context COVID-19, not only impairs viral clearance but also promotes paradoxically hyperinflammation including cytokine storm; an unfortunate event leading to organ failure following long term damage due inflammation even death.
منابع مشابه
Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Surgery, chemotherapy, and radiation therapy have been the foundation of cancer treatment. Advances in the field of immunology (a branch of science that studies all aspects of the immune system) have led to a greater understanding of the ways in which the body’s own defenses can be used for treatment of blood cancers. Cancer researchers are now studying how the immune system can help destroy ca...
متن کاملAdvancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects
Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs ...
متن کاملChimeric antigen receptor T-cell therapy to target hematologic malignancies.
Several decades of humoral immunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culminated in a successful merger: the development and clinical application of genetically engineered antibody-T cell chimeras. Also known as chimeric antigen receptor T cells (CAR T cells), these entities combine the exquisite antigen specificit...
متن کاملPredominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
UNLABELLED Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ malignancies. However, the etiological nature of neurologic complications remains a conundrum. In our study, the evidence of blood-brain barrier (BBB)-penetrating CAR T cells as a culprit was revealed. A patient with acute lymphocytic leukemia developed sustained pyre...
متن کاملPleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
RATIONALE Cytokine release syndrome (CRS) is a common and potentially fatal complication of CAR-T cell therapy. However, compartment CRS is relatively rare in hematological malignancies, as well as in solid tumors. The pathogenesis and prognosis of compartment CRS are unclear and there is no standardized treatment yet. In this case report, we will introduce a patient developing pleural cavity C...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International journal of immunology and immunotherapy
سال: 2023
ISSN: ['2378-3672']
DOI: https://doi.org/10.23937/2378-3672/1410068